Characterization and long-term persistence of immune response following two doses of an AS03 A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 2, 2012, Pages 238-244

  Ikematsu, Hideyuki ^a   Nagai, Hideaki ^b   Kawashima, Masahiro ^b   Kawakami, Yasunobu ^a   Tenjinbaru, Kazuyoshi ^c   Li, Ping ^d   Walravens, Karl ^e   Gillard, Paul ^e   Roman, François ^e  

^a KYUSHU UNIVERSITY   (Japan)

^b TOKYO NATIONAL HOSPITAL   (Japan)

^c Development and Medical Affairs Division   (Japan)

^d GLAXOSMITHKLINE   (United States)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adjuvant; AS03; H1N1; Long term; Pandemic; Persistence

Indexed keywords

ALPHA TOCOPHEROL; HEMAGGLUTINATION INHIBITING ANTIBODY; HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; OIL; WATER; AS03; INFLUENZA VIRUS HEMAGGLUTININ; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG SAFETY; FEMALE; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; JAPANESE; MALE; MICRONEUTRALIZATION ASSAY; NORMAL HUMAN; OPEN STUDY; PANDEMIC INFLUENZA; RHINOPHARYNGITIS; SEROCONVERSION; SEROPROTECTION; STRATIFIED SAMPLE; URTICARIA; VACCINATION; AGE DISTRIBUTION; ANIMAL CELL; CLINICAL TRIAL (TOPIC); DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FOLLOW UP; HEMAGGLUTINATION INHIBITION TEST; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; NONHUMAN; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; JAPAN; MALE; MIDDLE AGED; TIME FACTORS; VACCINATION; YOUNG ADULT;

EID: 84858184908     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.8.2.18469     Document Type: Article

References (28)

1. Ministry of Health. Labour and Welfare (MHLW); Press Release (April 28, 2010). Available: http://www.mhlw.go.jp/kinkyu/kenkou/influenza/houdou/2010/04/ dl/infuh0428-01.pdf. Accessed July 15, 2011. Japanese.
2. Ministry of Health. Labour and Welfare (MHLW); Press Release (February 05, 2010). Available: http://www.mhlw.go.jp/kinkyu/kenkou/influenza/houdou/2010/ 02/dl/infuh0205-05.pdf. Accessed July 15, 2011. Japanese.
3. Ministry of Health. Labour and Welfare (MHLW); Press Release (August 11, 2010). Available: http://www.mhlw.go.jp/kinkyu/kenkou/influenza/houdou/2010/08/ dl/infuh0811-01.pdf. Accessed July 15, 2011. Japanese.
4. Kamigaki T, Oshitani H. Epidemiological characteristics and low case fatality rate of pandemic (H1N1) 2009 in Japan. PLoS Curr 2009; 1:RRN1139; PMID: 20043033; http://dx.doi.org/10.1371/currents.RRN1139
5. Wada K, Nishiura H, Kawana A. An epidemiological analysis of severe cases of the influenza A (H1N1) 2009 virus infection in Japan. Influenza Other Respi Viruses 2010; 4:179-86; PMID:20836793; http://dx.doi.org/10.1111/j.1750-2659. 2010.00143.x
6. Kawai N, Ikematsu H, Iwaki N, Satoh I, Kawashima T, Maeda T, et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis 2005; 40:1309-16; PMID:15825034; http://dx.doi.org/10.1086/429241
7. Kawai N, Ikematsu H, Iwaki N, Maeda S, Satoh I, Hirotsu N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 2006; 43:439-44; PMID:16838232; http://dx.doi.org/10.1086/505868
8. Kawai N, Ikematsu H, Hirotsu N, Maeda T, Kawashima T, Tanaka O, et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin Infect Dis 2009; 49:1828-35; PMID:19911968; http://dx.doi.org/10.1086/648424
9. World Health Organization (WHO). Global Alert and Response (GAR). Pandemic influenza A (H1N1) 2009 virus vaccine - conclusions and recommendations from the October 2009 meeting of the immunization Strategic Advisory Group of Experts, December 04, 2009. Available at: http://www.who.int/csr/disease/ swineflu/meetings/sage-oct-2009/en/. Accessed July 15, 2011.
10. World Health Organization (WHO). WHO recommendations on pandemic (H1N1) 2009 vaccines. Pandemic (H1N1) 2009: briefing note 2. Available at: http://www.who.int/csr/disease/swineflu/notes/h1n1-vaccine-20090713/en/index. html. Accessed July 15, 2011.
11. Chu DWS, Hwang SJ, Lim FS, Oh HML, Thongcharoen P, Yang PC, et al. Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine. A phase III study in a large population of Asian adults. Vaccine 2009; 27:7428-35; PMID: 19683087; http://dx.doi.org/10.1016/j.vaccine.2009.07.102
12. Nagai H, Ikematsu H, Tenjinbaru K, Maeda A, DraméM, Roman FP. A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults. BMC Infect Dis 2010; 10:338; PMID:21108818; http://dx.doi.org/10.1186/ 1471-2334-10-338
13. Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine. PLoS ONE 2008;3:e1665.
14. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03(A)- trial. adjuvant: Preliminary report of an observer-blind, randomized controlled trial. Vaccine 2010; 28:1740-5; PMID: 20034605; http://dx.doi.org/10.1016/j.vaccine.2009.12.014
15. Carmona A, Oménaca F, Tejedor JC, Merino JM, Vaman T, Dieussaert I, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010; 28:5837-44; PMID:20600478; http://dx.doi.org/10.1016/j.vaccine.2010.06.065
16. Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Maeda A, et al. Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan. Hum Vaccin 2010; 6:888-93; PMID:20980795; http://dx.doi.org/10.4161/hv.6.11.12851
17. A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011; 11:91-101; PMID:21168369; http://dx.doi.org/10.1016/S1473-3099(10)70296-6
18. Madhun AS, Akselsen PE, Sjursen H, Pedersen G, Svindland S, Nøstbakken JK, et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 2010; 29:266-73; PMID:21034828; http://dx.doi.org/10.1016/j.vaccine.2010.10.038
19. World Health Organization (WHO). Influenza A (H1N1) 2009 virus: current situation and postpandemic recommendations. Wkly Epidemiol Rec 2011; 86:61-65; PMID:21337809
20. Nicholson KG, Abrams K, Batham S, Clark T, Hoschler K, Lim W, et al. A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart. Health Technol Assess 2010; 14:193-334; PMID: 21208550
21. Han T, Marasco WA. . Structural basis of influenza virus neutralization. Ann NY Acad Sci 2011. Ahead of Print. PMID:21251008; http://dx.doi.org/10.1111/ j.1749-6632.2010.05829.x
22. Stephenson I, Heath A, Major D, Newman RW, Hoschler K, Junzi W, et al. Reproducibility of Serologic Assays for Influenza Virus A (H5N1). Emerg Infect Dis 2009; 15:1252-9; PMID:19751587; http://dx.doi.org/10.3201/eid1508.081754
23. World Health Organization (WHO). Global Alert and Response (GAR). Pandemic influenza A (H1N1) 2009 virus vaccine - conclusions and recommendations from the October 2009 meeting of the immunization Strategic Advisory Group of Experts, December 04, 2009. Available: http://www.who.int/csr/disease/swineflu/ meetings/sage-oct-2009/en/. Accessed July 15, 2011.
24. Hehme NW, Künzel W, Petschke F, Gisela T, Carmen R, Christian Van H, et al. Ten years of experience with the trivalent split-influenza vaccine, FluarixTM. Clin Drug Investig 2002; 22:751-69; http://dx.doi.org/10.2165/ 00044011-200222110-00004
25. Baras B, de Waal L, Stittelaar KJ, Jacob V, Giannini S, Kroeze EJ, et al. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets. Vaccine 2011; 29:2120-6; PMID:21238573; http://dx.doi.org/10.1016/j.vaccine.2010.12.125
26. Reed LT, Muench H. A simple method of calculating fifty percent end point. Am J Hyg 1938; 27:493-8.
27. European Committee for Proprietary Medicinal Products (CHMP). Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006). European Agency for the Evaluation of Medicinal Products, January 24, 2007.
28. US Food and Drug Administration. (FDA) Guidance for Industry. Clinical data needed to support the licensure of pandemic influenza vaccines. US Food and Drug Administration May 2007. Available: http://www.fda.gov/cber/gdlns/ panfluvac.htm. Accessed July 15, 2011.